Navigation Links
Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
Date:1/29/2009

ANN ARBOR, Mich., Jan. 29 /PRNewswire/ -- Scientists at NanoBio Corp. and the University of Michigan have demonstrated in the laboratory that their novel topical nanoemulsion kills the highly resistant strains of bacteria that cause chronic illness and death among individuals with cystic fibrosis.

The findings are significant because they represent a new model for treating resistant bacteria that lead to pulmonary failure in patients with cystic fibrosis, according to the study authors. Results of the in vitro study are published in the January issue of Antimicrobial Agents and Chemotherapy.

"Respiratory tract infections are the primary cause of death in persons with cystic fibrosis, and there are simply no effective therapies for patients infected with Burkholderia and other bacterial species that are resistant to all known antibiotics," said John LiPuma, M.D., professor and associate chair for research in the department of pediatrics at the University of Michigan. "The nanoemulsion we tested was bactericidal against all but two of 150 bacterial strains, regardless of their levels of resistance, and it inhibited the growth of all the strains."

Currently, oral or intravenous antibiotics serve as frontline therapy against cystic fibrosis-related bacterial infections. But systemic drugs often fail to reach the airways with sufficient strength to subdue the bacteria or to penetrate the thick sputum and bacterial biofilms that coat the bacteria. The rising prevalence of drug-resistant strains of bacteria has also reduced the efficacy of frontline antibiotics, both oral and intravenous, according to LiPuma, lead author of the study.

In the present study, the scientists applied various concentrations of NanoBio's topical nanoemulsion to 150 multi-drug resistant and panresistant (completely resistant) bacteria obtained from the lungs of patients with cystic fibrosis. All strains of bacteria except two were killed by a concentration representing one-sixteenth the nanoemulsion formulation that has been used by NanoBio in recent clinical trials to treat skin infections.

"The strength of a topical or inhaled therapy is that you can achieve high local concentrations of the drug that you could never achieve with an oral systemic drug because it would cause systemic toxicity," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "We can nebulize our nanoemulsion so that it is deposited directly into the lungs to kill these highly resistant infections that cannot be effectively treated with available antibiotics."

The nanoemulsion also demonstrated bactericidal activity in the presence of cystic fibrosis sputum and against bacterial biofilms, protective coatings that surround bacterial colonies and block the penetration of drugs.

"Based on preclinical and clinical safety data from NanoBio's topical anti-infective products, we believe that we can safely deliver nanoemulsion concentrations to the lung that will be effective in killing the targeted bacteria," said LiPuma. "The goal is to reduce bacterial populations to a level that the body can effectively manage so that the patient has fewer acute episodes and hospitalizations."

NanoBio, a spin-out from the University of Michigan, is currently conducting preclinical nebulization and toxicity studies with multiple nanoemulsion formulations. The company expects to initiate a phase 1 study in humans with cystic fibrosis in 2010.

About NanoBio

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatology products, anti-infectives and intranasal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne and cystic fibrosis and a broad range of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
2. Vision Problems Affect How Children Learn Math Skills
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
5. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
6. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
9. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
10. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
11. VA National Campaign Takes Aim at Resistant Staph Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016   Arena Pharmaceuticals, Inc. (NASDAQ: ... enrollment in the ralinepag phase 2 trial.  Ralinepag is ... pathway for the treatment of pulmonary arterial hypertension (PAH). ... "This marks an important step in the ... focus on our pipeline," said Amit Munshi , ...
(Date:12/7/2016)... Dec. 7, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... Homecare Federation, At-Home IV Infusion Professional, BioRx, MedPro Rx, and XAS ... services, visit diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... "As we continue to build on the ...
(Date:12/7/2016)... , Dec. 7, 2016   Rx Savings Solutions ... and its Public Employees Insurance Agency (PEIA) to ... to their innovative healthcare software, ultimately saving money on their ... and provide its members with access to our software that ... more effective, affordable therapy can be found," says Michael ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Children ... bodies, a researcher at the Icahn School of Medicine at Mount Sinai has ... found that when young children are exposed to secondhand marijuana smoke, measurable amounts ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... acquired Presence Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 ... other considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, ...
(Date:12/7/2016)... ... 2016 , ... A quote from Dr. Edward Hallowell, host of CRN International’s ... offer a rare glimpse into the mind of those people with ADHD. , Dr. ... author, has described people with ADHD as having “Ferrari engines for a brain, with ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, a worldwide ... US market its advanced highly customizable contact technology solutions. , ODU Single Contact ... technologies are ideal for a wide range of applications that require customization from ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from Glen Burnie, ... is painful for her. "This is why the co-inventor and I have designed a ... They then created a prototype of the patent-pending AV-AIR, a device that serves as ...
Breaking Medicine News(10 mins):